NVWM LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

NVWM LLC’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$706	Hold	171	–	–	﹤0.01%	680
2026 Q2	$628	Hold	171	–	–	﹤0.01%	659
2026 Q1	$525	Hold	171	–	–	﹤0.01%	648
2025 Q4	$699	Hold	171	–	–	﹤0.01%	615
2025 Q3	$834	Hold	171	–	–	﹤0.01%	551
2025 Q2	$865	Hold	171	–	–	﹤0.01%	536
2025 Q1	$905	Hold	171	–	–	﹤0.01%	504
2024 Q4	$1.16K	Hold	171	–	–	﹤0.01%	446
2024 Q3	$1.13K	Hold	171	–	–	﹤0.01%	451
2024 Q2	$1.28K	Hold	171	–	–	﹤0.01%	406
2024 Q1	$1.7K	Buy	171 +48	+39%	+$535	﹤0.01%	366
2023 Q4	$1.21K	Hold	123	–	–	﹤0.01%	373
2023 Q3	$941	Buy	+123	New	+$1.23K	﹤0.01%	399

Other funds holding RXRX

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Values First Advisors Gray, Tennessee $213M AUM 20.51% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return

Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return

Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return

NVWM LLC's RXRX Position: Q3 2026 in Review

NVWM LLC held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 171 shares worth $706. The position accounts for ﹤0.01% of the portfolio, ranked #680.

NVWM LLC first reported a position in RXRX in Q3 2023 and has held it in 13 quarters since. The position peaked at $1.7K in Q1 2024. 69 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

NVWM LLC held 171 shares of Recursion Pharmaceuticals worth $706 as of Q3 2026.
NVWM LLC left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
Recursion Pharmaceuticals made up ﹤0.01% of NVWM LLC's portfolio in Q3 2026, its #680 holding.
NVWM LLC first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 13 quarters since.
NVWM LLC's Recursion Pharmaceuticals position peaked at $1.7K in Q1 2024.
69 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on NVWM LLC's 13F filing for Q3 2026, filed 14 Oct 2026.